Why Am I Not Losing Weight on Wegovy? Nine Reasons, a Diagnostic Table and What the Trials Call Normal

Written by Diana Gangan. Updated October 27, 2026.

If you are not losing weight on Wegovy, the first question is not why but when. In the first eight to twelve weeks you are on starting doses that are not meant to produce much weight loss, and the trials show that most of the result arrives between months three and twelve on the full 2.4 mg dose. The second question is how much counts as not losing. In the STEP 1 trial, 86% of people lost at least 5% of their body weight by 68 weeks, which means 14% did not, and that group is real and worth understanding. Between those two facts sit nine specific reasons a person on Wegovy sees the scale stall: under-dosing, a plateau that is actually normal, diabetes, other medicines, calorie creep, sleep, a product or storage problem, water and muscle, and the small group for whom semaglutide simply does not work and tirzepatide might.

This guide gives you a way to tell them apart. Start with the timeline, check your weight loss against the trial numbers, then use the diagnostic table to match what you are seeing with the likeliest cause and the fix.

Wegovy's dose ladder is 0.25 mg for four weeks, 0.5 mg for four, 1 mg for four, 1.7 mg for four, then 2.4 mg from month five. The low doses exist to let the gut adapt, and they do not produce much weight loss; in the trials, people had lost about 2% by week 4 and about 6% by week 12, with the steep part of the curve arriving once they reached the higher doses. If you are in month two and have lost three pounds, you are on schedule. The whole curve, month by month, is in how long Wegovy takes to work, and the dose schedule with what to do about missed shots is in the Wegovy dosing schedule.

This is the commonest reason by far and the easiest to miss, because people feel the appetite effect from the first injection and assume the drug is fully working. It is not. The STEP trials compared 2.4 mg with lower doses, and the difference is large: at 1 mg, semaglutide produces about 7% loss in people with diabetes; at 2.4 mg, about 10%; in people without diabetes the gap is similar. If supply problems, side effects or an insurer's step rules have parked you at 1 mg for months, the stall has a simple explanation. Some people do need to stay at a lower dose for tolerability, and the label allows a 1.7 mg maintenance dose, but the comparison is with 2.4 mg, not with doing nothing.

In every semaglutide trial the weight curve flattens between weeks 50 and 70. That is not the drug wearing off; blood levels are unchanged. It is the body reaching a new equilibrium at a lower weight, where a smaller body burns fewer calories and the reduced intake now matches it. A plateau after losing 12 to 15% is the trial outcome. The decision at that point is whether the weight you have reached is enough for your health goals, and if it is not, whether a stronger drug or a structured period of resistance training to raise resting metabolism makes sense. What a plateau is not is a reason to stop; stopping is what reverses the loss, as the withdrawal data in what happens when you stop taking Wegovy shows.

Semaglutide reduces hunger; it does not police what you eat when you are not hungry. The three-month honeymoon, when food genuinely does not appeal, fades for most people into a state where small portions are easy but a second helping, a glass of wine or an evening of grazing is entirely possible, and liquid calories slide past the fullness signal altogether. A two-week food log, written down rather than remembered, is the single most informative thing a stalled person can do, and it usually finds 300 to 500 calories a day nobody was counting. Protein matters because it is filling and protects muscle; aim for a palm-sized portion at every meal. Sleep matters because under six hours a night raises ghrelin, the hunger hormone, and lowers leptin, which partly undoes what the drug is doing. Diabetes and weight-promoting medicines are the two reasons that need a prescriber: insulin and sulfonylureas push the body toward fat storage, and a long list of common drugs, from mirtazapine to prednisone to some beta blockers, add weight. None of these should be stopped on your own, but all can be reviewed. Five practical levers are set out in five ways to boost weight loss on Wegovy.

Branded Wegovy is a consistent dose of semaglutide. Compounded semaglutide is not guaranteed to be: FDA testing and independent analyses have found under-dosed vials, wrong salts and vials with no detectable drug. If you are on a compounded product and not losing, the product is the first suspect. Branded pens have their own failure modes: a pen that froze in the fridge's back wall, sat in a hot car, or has been out of refrigeration for more than 28 days may deliver less than its dose, and a pen lifted off the skin before the yellow bar stopped moving delivers a partial one. The storage rules are in how long Wegovy can be out of the fridge, and the two clicks and the yellow bar are explained in how to use the Wegovy pen.

Body weight on any given morning swings by one to two kilograms with salt, carbohydrates, hormones, bowel contents and hydration, and people who start lifting weights on Wegovy, which they should, add muscle that weighs more than the fat it replaces. A tape measure around the waist, monthly photos in the same clothes and the fit of a specific pair of trousers are better instruments for a four-week trend than the daily number. Weigh once a week, same day, same time, after the bathroom and before breakfast, and judge the direction over a month.

About one person in seven in the trials lost less than 5% of their body weight despite full dosing, and roughly one in ten lost essentially nothing. Nobody fully understands why; genetics, gut hormone signalling and the degree to which a person's eating is driven by hunger rather than habit all seem to play a part. The practical definition is under 5% lost after three months at 2.4 mg with good adherence and no obvious cause from the list above. At that point the evidence favours switching rather than persisting: in the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% weight loss against 13.7% for semaglutide, and people who responded poorly to one GLP-1 drug often respond to the dual-agonist. The comparison is in Zepbound vs Wegovy; coverage rules for a switch are in does insurance cover Wegovy.

Not losing weight on Wegovy usually has a boring explanation: you are not at 2.4 mg yet, you have reached the plateau the trials predicted, or calories have crept back in. Those three cover most stalls and all three have fixes that do not involve changing the drug. Diabetes, medicines, sleep, product quality and the scale's daily noise account for most of the rest. What remains is the one person in seven for whom semaglutide does not work well, and for them the answer in 2026 is a different drug, not more patience. Check the timeline, check the dose, log the food for two weeks, and then decide. What a realistic result looks like for someone who does respond is in how much weight you can lose on Wegovy.

General information from published trials and labels; not a substitute for advice from your prescriber.